Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
暂无分享,去创建一个
J. Armitage | P. Yarnold | K. Knopf | C. Bennett | D. Raisch | C. Nabhan | O. Sartor | Y. T. Yang | W. Hrushesky | R. Kane | S. Luminari | B. Love | C. DeAngelis | Anuhya Kommalapati | S. Hoque | L. Norris | S. Tella | Brian Y. Chen | B. Witherspoon | S. Nagai | Paul S. Ray | L. Bobolts | A. Godwin | Joshua J Riente
[1] C. Bennett,et al. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? , 2019, JAMA oncology.
[2] C. Bennett,et al. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition , 2018, Drugs.
[3] Karol Sikora,et al. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. , 2018, The oncologist.
[4] R. Frank. Friction in the Path to Use of Biosimilar Drugs. , 2018, The New England journal of medicine.
[5] R. Schilsky,et al. American Society of Clinical Oncology Statement: Biosimilars in Oncology. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] K. Blackwell,et al. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] A. Sarpatwari,et al. The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics. , 2018, JAMA internal medicine.
[8] C. Nabhan,et al. Behavioral Economics and the Future of Biosimilars. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] C. Bennett,et al. Biosimilars—Curb Your Enthusiasm , 2017, JAMA oncology.
[10] C. Bennett,et al. Challenges to Biosimilar Substitution. , 2017, JAMA.
[11] S. Toyoshima,et al. Comparative study of the number of report and time‐to‐onset of the reported adverse event between the biosimilars and the originator of filgrastim , 2017, Pharmacoepidemiology and drug safety.
[12] J. Ross,et al. Obstacles to the Adoption of Biosimilars for Chronic Diseases. , 2017, JAMA.
[13] J. Woodcock,et al. Biosimilars: The US Regulatory Framework. , 2017, Annual review of medicine.
[14] M. Toumi,et al. Key drivers for market penetration of biosimilars in Europe , 2016, Journal of market access & health policy.
[15] Peter J. Pitts,et al. 21st century pharmacovigilance: efforts, roles, and responsibilities. , 2016, The Lancet. Oncology.
[16] Scott Stern,et al. The Impact of the Entry of Biosimilars: Evidence from Europe , 2016 .
[17] P. Paubel,et al. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience , 2016, PharmacoEconomics.
[18] Brian J Malkin. Biosimilars patent litigation in Canada and Japan: a comparative strategic overview and EU and US update , 2016 .
[19] M. Aapro,et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] S. Morgan,et al. Postmarket policy considerations for biosimilar oncology drugs. , 2016, The Lancet. Oncology.
[21] A. Zelenetz. Biosimilars in Oncology , 2016 .
[22] F. Jung,et al. Products , 1968, ADHESION ADHESIVES&SEALANTS.
[23] Brian J Malkin. Biosimilars patent litigation in the EU and the US: a comparative strategic overview , 2015 .
[24] Thomas J. Smith,et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Armitage,et al. Regulatory and clinical considerations for biosimilar oncology drugs. , 2014, The Lancet. Oncology.
[26] L. Usvyat,et al. Anaphylaxis and hypotension after administration of peginesatide. , 2014, The New England journal of medicine.
[27] J. Armitage,et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. , 2013, The New England journal of medicine.
[28] A. Ardizzoni,et al. Colony-stimulating factors for febrile neutropenia. , 2013, The New England journal of medicine.
[29] " Guideline for the Quality , Safety and Efficacy Assurance of Follow-on Biologics , 2013 .
[30] C Barbui,et al. What is the European Medicines Agency? , 2012, Epidemiology and Psychiatric Sciences.
[31] N. Kearney,et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.
[32] U. Gatzemeier,et al. Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma , 2009, Oncology Research and Treatment.
[33] U. Gatzemeier,et al. XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[34] A. Giglio,et al. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy , 2009, Leukemia & lymphoma.
[35] E. Lilly. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare , 2009 .
[36] Allen R Nissenson,et al. Pure red-cell aplasia and epoetin therapy. , 2004, The New England journal of medicine.
[37] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.
[38] Daniel R. Masys,et al. UNIVERSITY OF CALIFORNIA, SAN DIEGO , 2001 .
[39] J. Gabrilove,et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.